Under the same treatment with gefitinib, the growth rate and weight of the tumor in the ANGPTL4-shRNA + G group were lower than those in the control + G group (p < 0.05, Figures 4(d) and 4(e)). This evidence concerns the gene ANGPTL4 and neoplasm.